Pulmonary Drug Delivery Devices MarketGlobal Industry Analysis, Share, Size, Growth, Trends and Forecast 2017 - 2019
Global Pulmonary Drug Delivery Devices Market: Overview
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global pulmonary drug delivery devices market with respect to the leading market segments based on major products, key applications, distribution channels, and geographies.
Global Pulmonary Drug Delivery Devices Market: Segmentation
The global pulmonary drug delivery devices market has been studied based on major product type, application segments, major distribution channels, and regional as well as national markets. Based on product type, the global market has been categorized into three major segments: Dry Powder Inhalers, Metered Dose Inhalers and Nebulizers. Based on application, the global market has been categorized into four segments: Asthma, COPD, cystic fibrosis, and others. Based on distribution channels, the global market has been categorized into three key segments: retail pharmacies, hospital pharmacies, and e-commerce.
The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2019 along with the compound annual growth rate (CAGR %) from 2017 to 2019 are provided for all segments, considering 2016 as the base year.
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global pulmonary drug delivery devices market and could influence the market in the near future. Market attractiveness analysis has been provided in all the sections of the report in order to explain the intensity of competition in the market across different products / applications / distribution channels / geographies.
Global Pulmonary Drug Delivery Devices Market: Regional Analysis
Geographically, the pulmonary drug delivery devices market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). Each regional market for pulmonary drug delivery devices market has been further categorized into major product, application, and end-user segments considered within the scope of the study.
Key country (U.S., Japan, Germany, France, U.K., Australia, Canada, China, Brazil, Mexico, India, etc.) market revenues have also been provided in different regional sections within the report. Market revenue in terms of US$ Mn for the period from 2014 to 2019 along with CAGR % from 2017 to 2019 are provided for all the regions and nations considering 2016 as the base year.
Global Pulmonary Drug Delivery Devices Market: Competitive Outlook
The competitive scenario among different market players is evaluated through market share analysis in the competition landscape section of the pulmonary drug delivery devices market report. The section also includes competition matrix that analyzes the competition among some of the top global players operating in the market. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global pulmonary drug delivery devices market.
The report also profiles key players operating in the pulmonary drug delivery devices market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include AstraZeneca plc, Novartis AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, 3M Healthcare, Omron Corporation, and others.
Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.